Dialysis provider Fresenius Medical Care didn’t cause the death of a patient at a clinic, a Massachusetts jury found last week.
The decision came one year after Fresenius agreed to pay $250 million to settle thousands of lawsuits from dialysis patients and their families claiming the company’s treatments caused cardiac arrest and sometimes death. The Massachusetts case is the first bellwether trial over the issue. Fresenius initially came under fire in 2012 for its GranuFlo treatment after the company sent a memo to its doctors warning the product was contributing to an increase of patients dying from cardiac arrest. The Food and Drug Administration launched an investigation shortly afterward. Fresenius eventually recalled the product. More than 10,000 lawsuits were filed, most of which were settled.